GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products. Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies. Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world's largest selection of coronavirus research-grade products.